Literature DB >> 21107110

Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).

Seung-Gu Yeo1, Dae Yong Kim, Tae Hyun Kim, Hee Jin Chang, Jae Hwan Oh, Won Park, Doo Ho Choi, Heerim Nam, Jun-Sang Kim, Moon-June Cho, Jong Hoon Kim, Jin-Hong Park, Min Kyu Kang, Woong Sub Koom, Jae-Sung Kim, Taek-Keun Nam, Eui Kyu Chie, Jung Soo Kim, Kyung-Ja Lee.   

Abstract

OBJECTIVE: To investigate long-term outcomes of locally advanced rectal cancer (LARC) patients with postchemoradiotherapy (post-CRT) pathologic complete response of primary tumor (ypT0) and determine prognostic significance of post-CRT pathologic nodal (ypN) status.
BACKGROUND: LARC patients with post-CRT pathologic complete response were suggested to have favorable long-term outcomes, but prognostic significance of ypN status has never been specifically defined in ypT0 patients.
METHODS: The Korean Radiation Oncology Group collected clinical data for 333 LARC patients with ypT0 following preoperative CRT and curative radical resections between 1993 and 2007. Sphincter preservation surgery and abdominoperineal resection were performed in 283 (85.0%) and 50 (15.0%) patients, respectively. Postoperative chemotherapy was given to 285 (85.6%) patients. Survival was estimated by the Kaplan-Meier method, and the Cox proportional hazard model was used in multivariate analyses.
RESULTS: After median follow-up of 43 (range = 14-172) months, 5-year disease-free survival (DFS) was 84.6% and overall survival (OS) was 92.8%. The ypN status was ypT0N0 in 304 (91.3%), ypT0N1 in 22 (6.6%), and ypT0N2 in 7 (2.1%) patients. The ypN status was the most relevant independent prognostic factor for both DFS and OS in ypT0 patients. The 5-year DFS and OS was 88.5% and 94.8% in ypT0N0 patients, and 45.2% and 72.8% in ypT0N+ patients (both, P < 0.001).
CONCLUSIONS: LARC patients achieving ypT0N0 after preoperative CRT had favorable long-term outcomes, whereas positive ypN status had a poor prognosis even after total regression of primary tumor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107110     DOI: 10.1097/SLA.0b013e3181f3f1b1

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  67 in total

Review 1.  Transanal Minimally Invasive Surgery.

Authors:  Teresa deBeche-Adams; George Nassif
Journal:  Clin Colon Rectal Surg       Date:  2015-09

2.  Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study.

Authors:  Pengju Chen; Yunfeng Yao; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2015-08-18       Impact factor: 2.571

Review 3.  Current evidence regarding the role of adjuvant chemotherapy in rectal cancer patients with pathologic complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Ioannis Baloyiannis; Konstantinos Perivoliotis; Styliani Vederaki; Georgios Koukoulis; Dimitrios Symeonidis; George Tzovaras
Journal:  Int J Colorectal Dis       Date:  2021-03-27       Impact factor: 2.571

4.  Transanal Minimally Invasive Surgery (TAMIS): a clinical spotlight review.

Authors:  Teresa deBeche-Adams; Imran Hassan; Stephen Haggerty; Dimitrios Stefanidis
Journal:  Surg Endosc       Date:  2017-06-27       Impact factor: 4.584

5.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

6.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

7.  Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience.

Authors:  Matthias Zitt; Alexander DeVries; Josef Thaler; Reinhold Kafka-Ritsch; Wolfgang Eisterer; Peter Lukas; Dietmar Öfner
Journal:  Int J Colorectal Dis       Date:  2015-08-21       Impact factor: 2.571

8.  In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis.

Authors:  Hideki Ueno; Eiji Shinto; Yojiro Hashiguchi; Hideyuki Shimazaki; Yoshiki Kajiwara; Takahiro Sueyama; Junji Yamamoto; Kazuo Hase
Journal:  Virchows Arch       Date:  2015-03-29       Impact factor: 4.064

9.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

10.  Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.

Authors:  Byoung Yong Shim; Ji-Han Jung; Kang-Moon Lee; Hyung-Jin Kim; Sook Hee Hong; Sung Hwan Kim; Der Sheng Sun; Hyeon-Min Cho
Journal:  Int J Colorectal Dis       Date:  2012-07-31       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.